|
1
|
Matsuda T and Saika K: Comparison of time
trends in prostate cancer incidence (1973–2002) in Asia, from
cancer incidence in five continents, Vols IV–IX. Jpn J Clin Oncol.
39:468–469. 2009.
|
|
2
|
Kanai Y, Segawa H, Miyamoto K, Uchino H,
Takeda E and Endou H: Expression cloning and characterization of a
transporter for large neutral amino acids activated by the heavy
chain of 4F2 antigen (CD98). J Biol Chem. 273:23629–23632. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meier C, Ristic Z, Klauser S and Verrey F:
Activation of system L heterodimeric amino acid exchangers by
intracellular substrates. EMBO J. 21:580–589. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yanagida O, Kanai Y, Chairoungdua A, et
al: Human L-type amino acid transporter 1 (LAT1): characterization
of function and expression in tumor cell lines. Biochim Biophys
Acta. 1514:291–302. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fuchs BC and Bode BP: Amino acid
transporters ASCT2 and LAT1 in cancer: partners in crime? Semin
Cancer Biol. 15:254–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamauchi K, Sakurai H, Kimura T,
Wiriyasermkul P, Nagamori S, Kanai Y and Kohno N: System L amino
acid transporter inhibitor enhances anti-tumor activity of
cisplatin in a head and neck squamous cell carcinoma cell line.
Cancer Lett. 276:95–101. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sakata T, Ferdous G, Tsuruta T, et al:
L-type amino-acid transporter 1 as a novel biomarker for high-grade
malignancy in prostate cancer. Pathol Int. 59:7–18. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim DK, Ahn SG, Park JC, et al: Expression
of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain
(4F2hc) in oral squamous cell carcinoma and its precursor lesion.
Anticancer Res. 24:1671–1675. 2004.PubMed/NCBI
|
|
9
|
Kobayashi H, Ishii Y and Takayama T:
Expression of L-type amino acid transporter 1 (LAT1) in esophageal
carcinoma. J Surg Oncol. 90:233–238. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nawashiro H, Otani N, Shinomiya N, et al:
L-type amino acid transporter 1 as a potential molecular target in
human astrocytic tumors. Int J Cancer. 119:484–492. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nakanishi K, Ogata S, Matsuo H, et al:
Expression of LAT1 predicts risk of progression of transitional
cell carcinoma of the upper urinary tract. Virchows Arch.
451:681–690. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kaira K, Oriuchi N, Imai H, et al:
Prognostic significance of L-type amino acid transporter 1
expression in resectable stage I–III non-small cell lung cancer. Br
J Cancer. 98:742–748. 2008.
|
|
13
|
Takeuchi K, Ogata S, Nakanishi K, et al:
LAT1 expression in non-small cell lung carcinomas: analyses by
semiquantitative reverse transcription-PCR (237 cases) and
immunohistochemistry (295 cases). Lung Cancer. 68:58–65. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Furuya M, Horiguchi J, Nakajima H, Kanai Y
and Oyama T: Correlation of L-type amino acid transporter 1 and
CD98 expression with triple negative breast cancer prognosis.
Cancer Sci. 103:382–389. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaira K, Sunose Y, Segawa A, et al:
Prognostic significance of L-type amino acid transporter 1
expression in surgically resected pancreatic cancer. Br J Cancer.
107:632–638. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumors (UICC International Union
Against Cancer). 7th edition. Wiley-Blackwell; Oxford: 2009
|
|
17
|
Epstein JI, Allsbrook WC Jr, Amin MB and
Egevad LL; ISUP Grading Committee: The 2005 International Society
of Urological Pathology (ISUP) consensus conference on Gleason
grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Buck AC, Schirrmeister HH, Guhlmann CA, et
al: Ki-67 immunostaining in pancreatic cancer and chronic active
pancreatitis: does in vivo FDG uptake correlate with proliferative
activity? J Nucl Med. 42:721–725. 2001.PubMed/NCBI
|
|
19
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kaira K, Oriuchi N, Imai H, et al:
Prognostic significance of L-type amino acid transporter 1 (LAT1)
and 4F2 heavy chain (CD98) expression in stage I pulmonary
adenocarcinoma. Lung Cancer. 66:120–126. 2009. View Article : Google Scholar
|
|
21
|
D’Amico AV, Whittington R, Malkowicz SB,
et al: Biochemical outcome after radical prostatectomy, external
beam radiation therapy, or interstitial radiation therapy for
clinically localized prostate cancer. JAMA. 280:969–974. 1998.
|
|
22
|
Stark JR, Perner S, Stampfer MJ, et al:
Gleason score and lethal prostate cancer: does 3+4=4+3? J Clin
Oncol. 27:3459–3464. 2009.PubMed/NCBI
|
|
23
|
Wright JL, Salinas CA, Lin DW, Kolb S,
Koopmeiners J, Feng Z and Stanford JL: Prostate cancer specific
mortality and Gleason 7 disease differences in prostate cancer
outcomes between cases with Gleason 4+3 and Gleason 3+4 tumors in a
population-based cohort. J Urol. 182:2702–2707. 2009.
|
|
24
|
Laitinen S, Martikainen PM, Tolonen T,
Isola J, Tammela T and Visakorpi T: EZH2, Ki-67 and MCM7 are
prognostic markers in prostatectomy-treated patients. Int J Cancer.
122:595–602. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mastroberardino L, Spindler B, Pfeiffer R,
et al: Amino-acid transport by heterodimers of 4F2hc/CD98 and
members of a permease family. Nature. 395:288–291. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim DK, Kanai Y, Matsuo H, et al: The
human T-type amino acid transporter-1: characterization, gene
organization, and chromosomal location. Genomics. 79:95–103. 2002.
View Article : Google Scholar : PubMed/NCBI
|
